Oak Hill takes SPAC track to Nasdaq with Roche asset in tow Leave a Comment / By Leonardo Arias / 28/07/2026 Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
